ARC Fertility Announces New CEO

ARC® Fertility is bringing in Lissa Goldenstein as Chief Executive Officer to lead the growth of the largest national network of fertility clinics

Jan 20, 2016, 11:00 ET from ARC Fertility

SARATOGA, Cailf., Jan. 20, 2016 /PRNewswire/ -- Dr. David Adamson is pleased to extend executive leadership responsibilities to Lissa Goldenstein, who will be responsible for accelerating growth at ARC® Fertility (, building on the solid foundation and momentum achieved by the ARC team over the past 18 years. As founder of ARC, Dr. Adamson is continuing his leadership at ARC Fertility as Executive Chairman and Chief Medical Officer.

"ARC Fertility is creating and capturing opportunities in the growing reproductive medicine sector, and is expanding its products and services for fertility clinics and physicians as well as women and men suffering from infertility," says Dr. Adamson. "Lissa is a recognized leader in women's health and brings significant experience and partnerships in the fertility market. This, along with her 12 years experience as successful CEO leading multiple healthcare companies, makes her perfect for the CEO role during this important new phase for ARC."

Prior to her new position with ARC, Ms. Goldenstein was President and CEO of Auxogyn Inc. where she led the development and commercialization of the company's flagship product, the Eeva™ Test that is currently marketed in the US and in Europe. She previously held leadership roles as CEO with Artemis Health, Inc. (now Verinata Health, Inc.) and Argonaut Technologies Inc. successfully bringing new technologies to advance the healthcare field. In May, 2015 she joined the board of ARC Fertility.

Ms. Goldenstein will work closely with Dr. Adamson on broadening ARC's business strategy to further address the needs of patients, clinicians and providers supporting the infertility community. The appointment will allow Dr. Adamson to continue his focus on the medical contribution of ARC's extensive network of physicians in reproductive medicine as well as his significant role in the global fertility community, and as a practicing physician.

"The demand for evidence-based fertility products and services in the reproductive field is significant and my strong passion for information integrity in women's health and the fertility market makes this an ideal match," says Ms. Goldenstein. "This is a unique transition phase for ARC Fertility, and I am looking forward to working closely with Dr. Adamson, the ARC team, the ARC Network of Clinics and our strategic partners, to develop and deliver best-in-class products and services for those facing infertility."

About ARC® Fertility

ARC® Fertility is a trusted leader in the IVF fertility market providing innovative products and services to the infertility community. With more than 18 years of experience, ARC has the largest network of board-certified fertility specialists in the United States and supports women and couples on their infertility journey with best-in-class resources and tools on education and treatment. ARC provides patients with affordable, evidence-based fertility treatment packages, refund guarantees and finance, and has assisted more than 20,000 women struggling with infertility. In addition, ARC Fertility provides products and services to both IVF providers and large employers with the goal of making fertility more affordable and accessible to couples throughout the United States. ARC Fertility was founded in 1997 as Advanced Reproductive Care, Inc. by world-renowned, Stanford-trained, board-certified reproductive endocrinologist Dr. David Adamson. Please visit and follow the company on Twitter @ARCFertility.


SOURCE ARC Fertility